Advances in oral peptide therapeutics
DJ Drucker - Nature reviews Drug discovery, 2020 - nature.com
Protein and peptide therapeutics require parenteral administration, which can be a deterrent
to medication adherence. For this reason, there have been extensive efforts to develop …
to medication adherence. For this reason, there have been extensive efforts to develop …
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Y Li, Y Liu, S Liu, M Gao, W Wang, K Chen… - Signal transduction and …, 2023 - nature.com
Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …
treatment protocols based on a single vascular complication are no longer suitable for the …
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
IH de Boer, ML Caramori, JCN Chan… - Kidney …, 2020 - kidney-international.org
This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
Safety of semaglutide
MM Smits, DH Van Raalte - Frontiers in endocrinology, 2021 - frontiersin.org
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …
approved agent of this drug class, and the only GLP-1RA currently available as both …
Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial
OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral
semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared …
semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared …
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
TY Wang, RF Wang, ZY Bu, G Targher… - Nature Reviews …, 2022 - nature.com
Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of fat in more
than 5% of hepatocytes in the absence of excessive alcohol consumption and other …
than 5% of hepatocytes in the absence of excessive alcohol consumption and other …
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised …
VR Aroda, J Aberle, L Bardtrum, E Christiansen… - The Lancet, 2023 - thelancet.com
Background Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed
to investigate a new formulation of oral semaglutide at higher investigational doses versus …
to investigate a new formulation of oral semaglutide at higher investigational doses versus …
Wegovy (semaglutide): a new weight loss drug for chronic weight management
G Singh, M Krauthamer… - Journal of Investigative …, 2022 - journals.sagepub.com
Obesity is a growing epidemic within the USA. Because weight gain is associated with an
increased risk of develo** life-threatening comorbidities, such as hypertension or type 2 …
increased risk of develo** life-threatening comorbidities, such as hypertension or type 2 …
[HTML][HTML] Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics
especially peptides and proteins. In the intervening period, analysis of the preclinical and …
especially peptides and proteins. In the intervening period, analysis of the preclinical and …